AMTI logo

AMTI Stock

Profile

Full Name:

Applied Molecular Transport Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 June 2020

Indexes:

Not included

Website:

http://www.appliedmt.com

Description:

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$3.25(-21.72% YoY)

PE Ratio

-

Annual ROE

-207.64%

Annual Debt To Equity

0.59

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 08, 2024

Recent annual earnings:

Mar 08, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

28 Mar '23 Chardan Capital
Neutral
06 Mar '23 Chardan Capital
Buy
08 Feb '23 Jefferies
Underperform
05 Jan '23 B of A Securities
Underperform
27 Dec '22 SVB Leerink
Market Perform
23 Dec '22 JMP Securities
Market Perform
02 Dec '22 Chardan Capital
Buy
08 Nov '22 SVB Leerink
Outperform
07 July '22 Jefferies
Hold
20 May '22 SVB Leerink
Outperform

Screeners with AMTI included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$74.14
AMTI price is currently at an all-time high

Price Analysts Target

$1.00
AMTI price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

-350.47%
AMTI annual net profit is down -350.47% over the past 3 years

Annual EPS 3-Year Change

-147.83%
AMTI annual earnings per share is down -147.83% over the past 3 years

Annual Operating Profit

-$127.22 M
AMTI annual operaing income is -$127.22 million

Annual Operating Profit 3-Year Change

-349.7%
AMTI annual operaing income is down -349.7% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-207.64%
AMTI annual return on equity is -207.64%

Annual ROA

-117.57%
AMTI annual return on assets is -117.57%

Annual EBIT

-$127.22 M
AMTI annual earnings before interest & taxes is -$127.22 million

Annual EBITDA

-$124.09 M
AMTI annual earnings before interest, taxes, depreciation & amortization is -$124.09 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

4.24
AMTI annual current ratio is 4.24

Annual Total Assets

$107.45 M
AMTI annual total assets is $107.45 million

Annual Current Assets

$64.02 M
AMTI annual total current assets is $64.02 million

Annual Total Liabilities

$46.61 M
AMTI annual total liabilities is $46.61 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

-248.2%
AMTI annual cash flow from operations is down -248.2% over the past 3 years

Annual CFI 3-Year Change

+81.24%
AMTI annual cash flow from investing activities is up +81.24% over the past 3 years

Annual CFF 3-Year Change

-101.76%
AMTI annual cash flow from financing activities is down -101.76% over the past 3 years

Annual FCF

-$98.05 M
AMTI annual free cash flow is -$98.05 million

Annual FCF 3-Year Change

-236.72%
AMTI annual free cash flow is down -236.72% over the past 3 years

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of Applied Molecular Transport?
  • What is the ticker symbol for Applied Molecular Transport?
  • Does Applied Molecular Transport pay dividends?
  • What sector is Applied Molecular Transport in?
  • What industry is Applied Molecular Transport in?
  • What country is Applied Molecular Transport based in?
  • When did Applied Molecular Transport go public?
  • Is Applied Molecular Transport in the S&P 500?
  • Is Applied Molecular Transport in the NASDAQ 100?
  • Is Applied Molecular Transport in the Dow Jones?
  • When was Applied Molecular Transport's last earnings report?
  • When does Applied Molecular Transport report earnings?
  • Should I buy Applied Molecular Transport stock now?

What is the primary business of Applied Molecular Transport?

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.

What is the ticker symbol for Applied Molecular Transport?

The ticker symbol for Applied Molecular Transport is NASDAQ:AMTI

Does Applied Molecular Transport pay dividends?

No, Applied Molecular Transport does not pay dividends

What sector is Applied Molecular Transport in?

Applied Molecular Transport is in the Healthcare sector

What industry is Applied Molecular Transport in?

Applied Molecular Transport is in the Biotechnology industry

What country is Applied Molecular Transport based in?

Applied Molecular Transport is headquartered in United States

When did Applied Molecular Transport go public?

Applied Molecular Transport's initial public offering (IPO) was on 05 June 2020

Is Applied Molecular Transport in the S&P 500?

No, Applied Molecular Transport is not included in the S&P 500 index

Is Applied Molecular Transport in the NASDAQ 100?

No, Applied Molecular Transport is not included in the NASDAQ 100 index

Is Applied Molecular Transport in the Dow Jones?

No, Applied Molecular Transport is not included in the Dow Jones index

When was Applied Molecular Transport's last earnings report?

Applied Molecular Transport's most recent earnings report was on 8 March 2024

When does Applied Molecular Transport report earnings?

The date for Applied Molecular Transport's next earnings report has not been announced yet

Should I buy Applied Molecular Transport stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions